Compare MakeMyTrip Ltd (MMYT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Novo Nordisk A/S — how do they compare? MakeMyTrip Ltd trades at $49.2 (market cap $5.07B), while Novo Nordisk A/S trades at $44.72 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 39.6× MakeMyTrip Ltd's market cap, and Novo Nordisk A/S pays a 3.98% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| MMYT | NVO | |
|---|---|---|
Market Cap | $5.07B | $200.69B |
Sector | Technology | Health |
52-Week High | $101.86 | $63.98 |
52-Week Low | $36.30 | $35.29 |
Enterprise Value | $5.73B | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $53.90, down 3.09% today, showing technical bearish signals despite strong analyst support with 8 buy ratings. The company maintains solid revenue growth with $978M in 2025 revenue and $95M net income, though earnings volatility persists with mixed quarterly results. Recent news highlights institutional selling pressure despite positive industry outlook for internet delivery services.
Investment outlook remains cautiously optimistic given the 34% upside potential from analyst targets, but risks include declining cash flow trends and rising debt-to-asset ratios from 12% to 80% projected for 2026. The stock's high P/E ratio of 234 requires sustained earnings growth to justify valuation, making execution critical for future performance.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
